target protein News
-
Find A Way for Rapid Protein Expression with Creative BioMart’s Cell-free Expression System
Creative BioMart Heterologous Protein Expression, a new sub-brand of Creative BioMart, that’s equipped with supportive instruments and a professional technique team, now has developed a cell-free protein expression system to express and reproduce recombinant proteins more efficiently than traditional protein expression techniques. Compared with the traditional intracellular expression ...
-
Profacgen Updated Its E3 Ligase and Target Proteins Development Services
Profacgen has recently updated its E3 Ligase and Target Proteins Development Services, expanding the company’s portfolio of PROTAC development services. The updated services provide scientists with comprehensive advanced platform for their projects. The ubiquitin proteasome system relies heavily on E3 ligases (UPS). As a major modulator of protein homeostasis, UPS is essential in signal ...
By Profacgen
-
Profacgen Provides Protein Ubiquitination Services to Accelerate Drug Development Project
Profacgen, an experienced provider in biological research and drug discovery, provides various ubiquitin services to help customers accelerate research progress and obtain better results. Ubiquitination is one of the most prevalent post-translational modifications (PTMs) in cells. Ubiquitin modification induces protein degradation, which affects the function, localization, and activity of ...
By Profacgen
-
PharmCode for Precision in Target Validation
Vybion announces the availability of PharmCode for partnering. PharmCode provides precise and rapid targeting of protein-protein, dimerization, phosphorylation or allele specific intracellular events in a pharmacologically meaningful manner avoiding pleiotropic effects. Most targets have multiple interactions but PharmCode Intrabodies target single events and can assess pathway effects, pathway ...
By Vybion
-
Sibylla Biotech Raises €23 Million Series A to Advance Protein Degradation by Folding Interference Pipeline and Expand Technology Platform
Sibylla Biotech today announced the successful close of its €23 million Series A financing round to fund the further development of its Pharmacological Protein Inactivation by Folding Intermediate Targeting (PPI-FIT) approach, which provides access to a new class of pharmacological targets that transiently appear during the process of protein folding, and to advance its proprietary pipeline ...
-
CD Genomics: Targeted Proteomics Analysis Service Now Available by Bioinformatics-Analysis Platform
Bioinformatics-analysis Platform belongs to CD Genomics, which provides reliable next-generation and third-generation high-throughput sequencing data analysis, comprehensive technology services, database construction, and other related data analysis business. The platform is a leading open solution for data-driven innovation, which aims to discover hidden potential in biological data and unearth ...
By CD Genomics
-
New Research Collaboration with Janssen Biotech
Immune Biosolutions Inc. (IBio), a JLABS @ Toronto resident company, today announced a research collaboration and license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The agreement, facilitated by Johnson & Johnson Innovation LLC, will focus initially on the discovery and development of therapeutic antibodies in oncology. The ...
-
SilcsBio and Helix BioStructures Launch Partnership to Collaborate in Fueling Pharmaceutical Drug Design Opportunities
August 29, 2022, Baltimore, MD and Indianapolis, IN – SilcsBio, a technology company that develops and markets software and services for structure-based drug design, today announced the launch of a partnership with Helix BioStructures, a pharmaceutical-biotech contract research organization that provides high-quality, integrated drug discovery services to the pharmaceutical community in the ...
-
Profacgen Updated Its Membrane Protein Modeling Service Recently
Profacgen, a state-of-the-art protein service provider that provides custom protein services in the biological sciences, recently updated its membrane protein modeling service to better assist scientists in the field of structure-based protein engineering. Membrane proteins account for one third of all genes in the human genome, and they play critical roles as receptors, enzymes, ion channels, ...
By Profacgen
-
Patent Issues for Novel Huntington`s and Alzheimer`s Disease Gene Therapy
Vybion announces the issue by the USPTO of Patent No. 9932394 entitled, "Single Chain Intrabodies that Alter Huntingtin Mutant Degradation". Issued claims cover composition of matter as well as both the Huntingtin and Tau protein targets with the potential for treatment of both Huntington's and Alzheimer's diseases. A continuation on the remaining methods claims has been filed. This patent ...
By Vybion
-
Creative Biostructure Offers MagHelix™ FBDD Platform for Lead Discovery and Optimization
As an expert in the field of structural biology, Creative Biostructure offers MagHelix™ FBDD Platform, an integrated platform covering the entire FBDD process, equipped with advanced biophysical detection instruments, providing customized drug discovery solutions for a wide range of disease areas and therapeutic targets. Fragment-based drug discovery (FBDD) is a powerful approach to ...
-
Atomwise Partners with Global Research Teams to Pursue Broad-Spectrum Treatments Against COVID-19 and Future Coronavirus Outbreaks
Atomwise, the leader in using artificial intelligence (AI) for small molecule drug discovery, announced today it has fifteen research collaborations underway with leading global universities to explore broad-spectrum therapies for COVID-19 and other coronaviruses. Coronaviruses are RNA viruses and include the causative SARS-CoV-2 strain of the current COVID-19 global pandemic as well as MERS ...
-
Dicerna Announces Two Targets Meet Preclinical Proof of Principle Criteria in Neurodegeneration and Pain Under Global Research Collaboration and Licensing Agreement With Lilly
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Eli Lilly and Company (“Lilly”) has declared proof of principle for the first two targets in the companies’ exclusive relationship in neurodegeneration and pain, under the companies’ global research and licensing ...
-
Orion Completes Lead Optimization of its CCR2-Targeted Molecule in Only 6 Months!
Orion Biotechnology, a clinical stage company unlocking the therapeutic potential of G Protein-Coupled Receptors (GPCRs) with a novel drug modality, proven discovery platform and best-in-class molecules, today announced the successful completion of its OB-004 lead optimization. OB-004 is a GPCR targeted protein analog of CCL2 that targets the CCR2 receptor. The CCL2/CCR2 pathway plays an ...
-
Jeanette presents E-poster at IPVC 2021
The virtual 34th International Papillomavirus Conference took place last week, from November 15-19. The conference’s theme this year was: ‘Research and education for HPV elimination’. Jeanettes E-Poster ‘A Candidate Broadly Protective HPV-Vaccine Targeting the L2 Minor Protein Demonstrates Promising Results in a Clinical Phase I Trial’ was selected for the ...
-
Profacgen Launched Antibiotic-free Expression System for Protein Expression Service
Profacgen, a state-of-the-art protein service provider located in the USA that provides custom protein services in biological sciences, recently launched a new and highly effective antibiotic-free expression system to meet scientists’ needs in the protein expression field. Expression vectors inserted with antibiotic resistance genes are mainstream recombinant expression systems that use ...
By Profacgen
-
Creative Proteomics Unveils Revolutionary Co-IP Service Empowering Breakthroughs in Protein-Protein Interaction Research
Creative Proteomics, a global leader in proteomics services, proudly announces the launch of its cutting-edge Co-immunoprecipitation (Co-IP) service. This advanced offering enables researchers to explore protein-protein interactions and gain valuable insights into complex cellular processes. Protein-protein interactions are the cornerstone of numerous biological processes, playing a pivotal ...
-
Alex MacKerell, PhD, SilcsBio Co-founder & CSO, Co-Leads Study on Use of SILCS Technology to Improve Lung Disease Treatments
December 14, 2022, Baltimore, MD – SilcsBio, a technology company that develops and markets software and services for structure-based drug design, today announced its Co-Founder and Chief Scientific Officer, Alexander D. MacKerell Jr., PhD, has co-led a study focusing on improving respiratory treatments via SilcsBio’s Site Identification by Ligand Competitive Saturation (SILCS) ...
-
Nanobodies and CAR-T
Researchers from Boston Children’s Hospital and MIT took mini-antibodies from alpacas Bryson and Sanchez. Then they shrunk the mini-antibodies into even smaller nanobodies and engineered these nanobodies onto CAR-T cells. During this process, they discovered a new form of cell therapy. The goal is to enhance CAR-T cells’ targeting abilities by targeting immunosuppressive proteins in ...
By IMAPAC
-
CD ComputaBio Unveils Ligand-based Pharmacophore Model Service for Drug Design and Screening
CD ComputaBio, a reliable computational biology service provider located in New York, is always hammering away at research and trials in order to provide customers with access to the latest software, technologies, and expertise at a competitive price and fast turnaround time. The company recently announced the launch of ligand-based pharmacophore model service for scientists to accelerate the ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you